Literature DB >> 11367526

Structure/function of C5 convertases of complement.

N Rawal1, M K Pangburn.   

Abstract

C5 convertases are serine proteases that cleave both C3 and C5. Alternative pathway C3/C5 convertases formed with monomeric C3b (C3b,Bb) because of their weak interaction with C5 primarily cleave C3 thereby opsonizing the cell surface with C3b. In contrast, C3/C5 convertases formed with a high density of C3b/cell exhibit higher affinities for C5 as indicated by Km values well below the physiological concentration of C5 in blood. These C3/C5 convertases bind C5 efficiently and cleave it at a velocity approaching Vmax thereby switching the enzyme from C3 cleavage to production of the cytolytic C5b-9 complex. Studies of the structure of C3/C5 convertases have postulated that C4b-C3b and C3b-C3b dimers from high affinity C5 binding sites while indel studies have shown two binding sites in C5 for the convertase in addition to the C5 cleavage site. Together, these studies indicate that with increasing deposition of C3b on the surface, C3b complexes are formed which through multivalent attachment bind the substrate C5 with higher affinities, thereby converting the low affinity C3/C5 convertases to high affinity C5 convertases. The process underlying the formation of high affinity C5 convertases during complement activation is discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11367526     DOI: 10.1016/s1567-5769(00)00039-4

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  17 in total

1.  The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models.

Authors:  Masha Fridkis-Hareli; Michael Storek; Eran Or; Richard Altman; Suresh Katti; Fang Sun; Tao Peng; Jeff Hunter; Krista Johnson; Yi Wang; Ante S Lundberg; Gaurav Mehta; Nirmal K Banda; V Michael Holers
Journal:  Mol Immunol       Date:  2018-12-01       Impact factor: 4.407

2.  Convertase inhibitory properties of Staphylococcal extracellular complement-binding protein.

Authors:  Ilse Jongerius; Brandon L Garcia; Brian V Geisbrecht; Jos A G van Strijp; Suzan H M Rooijakkers
Journal:  J Biol Chem       Date:  2010-03-19       Impact factor: 5.157

3.  Complement activation in acetaminophen-induced liver injury in mice.

Authors:  Rohit Singhal; Patricia E Ganey; Robert A Roth
Journal:  J Pharmacol Exp Ther       Date:  2012-02-07       Impact factor: 4.030

Review 4.  How novel structures inform understanding of complement function.

Authors:  Elena Goicoechea de Jorge; Hugo Yebenes; Marina Serna; Agustín Tortajada; Oscar Llorca; Santiago Rodríguez de Córdoba
Journal:  Semin Immunopathol       Date:  2017-08-14       Impact factor: 9.623

Review 5.  Complement and Bacterial Infections: From Molecular Mechanisms to Therapeutic Applications.

Authors:  Dani A C Heesterbeek; Mathieu L Angelier; Richard A Harrison; Suzan H M Rooijakkers
Journal:  J Innate Immun       Date:  2018-08-27       Impact factor: 7.349

6.  C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.

Authors:  Allison Lesher Williams; Damodar Gullipalli; Yoshiyasu Ueda; Sayaka Sato; Lin Zhou; Takashi Miwa; Kenneth S Tung; Wen-Chao Song
Journal:  Kidney Int       Date:  2017-01-27       Impact factor: 10.612

Review 7.  Compstatins: the dawn of clinical C3-targeted complement inhibition.

Authors:  Christina Lamers; Dimitrios C Mastellos; Daniel Ricklin; John D Lambris
Journal:  Trends Pharmacol Sci       Date:  2022-01-25       Impact factor: 17.638

8.  Complement activation pathways in murine immune complex-induced arthritis and in C3a and C5a generation in vitro.

Authors:  N K Banda; B Levitt; A K Wood; K Takahashi; G L Stahl; V M Holers; W P Arend
Journal:  Clin Exp Immunol       Date:  2009-10-19       Impact factor: 4.330

Review 9.  Properdin in complement activation and tissue injury.

Authors:  Allison M Lesher; Bo Nilsson; Wen-Chao Song
Journal:  Mol Immunol       Date:  2013-06-29       Impact factor: 4.407

10.  Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor.

Authors:  Suzan H M Rooijakkers; Jin Wu; Maartje Ruyken; Robert van Domselaar; Karel L Planken; Apostolia Tzekou; Daniel Ricklin; John D Lambris; Bert J C Janssen; Jos A G van Strijp; Piet Gros
Journal:  Nat Immunol       Date:  2009-06-07       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.